CINCINNATI, May 07, 2024 (GLOBE NEWSWIRE) — Enable Injections, Inc. (“Enable”), a leading innovator in developing and manufacturing the enFuse^® platform of wearable drug delivery device technology, today announced the Company has expanded its partnership with Roche through a collaboration, allowing Roche to develop and apply Enable’s expertise and enFuse delivery technology to specific Roche development programs. Through this collaboration, Roche will obtain a worldwide, exclusive license to develop and commercialize combinations of the enFuse technology with specific Roche molecules. Enable will be responsible for clinical and commercial manufacturing and supply of the enFuse system.

enFuse is the first purely mechanical wearable drug delivery device technology designed to deliver large volumes of small molecule and biologic medications subcutaneously, whereby patients receive their needed treatment in a simple injection under the skin, instead of intravenously.

“IV infusions can be inconvenient and time-consuming for both patients and providers. This is especially true when treating chronic disorders, which require longer-term treatment and frequent trips to the clinic,” said Mike Hooven, Chairman and CEO of Enable Injections. “enFuse was designed to overcome IV infusion shortcomings through fast, simple, and convenient delivery, bringing efficiency and value to the entire spectrum of healthcare, including patients, providers, and payers, with the ability for at home self-administration.”

“We are pleased that Roche recognizes the significant value our wearable technology brings to the patient treatment experience and look forward to serving patients through the potential of our differentiated device delivery platform with Roche’s differentiated molecules,” continued Hooven.

View the original press release on Globe Newswire.